Holes in the heparin supply chain lead to deaths across the US

Dr. Margaret Hamburg, FDA Commissioner, details the FDA’s growing partnership with organizations, health authorities and governments in the Mekong Region to ensure safe food and medicine delivery to the US, while also improving medication reliability in the Mekong. Another highlight of how global supply chains are making national borders less relevant in this post-Westphalian globalized world we live in. The FDA’s cooperation represents a step in the right direction to derive  a benefit both for the US (whose taxpayers fund all this activity) as well as the citizens of the Mekong Region. As Commissioner Hamburg explains:

Though Americans may not often think about it, the U.S. is increasingly and inextricably linked to the Mekong Region through global supply chains. For instance, about 15% of the seafood we consume in the United States comes from Mekong region countries, arriving on our shores and in our stores after a long and circuitous journey. Consider tuna, which may be caught in the South Pacific, transported to New Zealand for pre-canning, and shipped to Southeast Asia for canning before it finally makes its way to the East Coast of the United States for distribution in this country.

Why does this matter to FDA? There is a greater likelihood that food will be exposed to pathogens, contaminants or chemical hazards during a journey of this complexity. That’s why we work closely with our regional counterparts in these countries through such organizations as the Association of Southeast Asian Nations (ASEAN) and the Asia Pacific Economic Cooperation (APEC), sharing with them our own regulatory requirements, our knowledge of good manufacturing practices and our laboratory and inspection techniques. Through such information sharing we believe we can prevent tainted or otherwise unsafe foods from reaching our borders.

But the risk of potentially unsafe food from this area is not our only concern. A significant threat to human safety today involves substandard, falsified and counterfeit medical products that are part of the global supply chain. These products may contain toxic ingredients, or too much or too little of a drug’s active ingredient, and as a result patients could be poisoned or unwittingly receive inadequate treatment for their disease or even no treatment at all. In addition, if too many patients receive only partial treatment, it might foster the development of drug-resistant disease strains. And there’s this too: a high prevalence of substandard and falsified medicines ultimately will erode public trust in the health care system.

See more at: http://blogs.fda.gov/fdavoice/index.php/tag/asia-pacific-economic-cooperation-apec/